CTLA4 and melanoma: Ipilimumab, a monoclonal antibody targeting CTLA-4, was the first immune checkpoint inhibitor (ICI) to receive FDA approval, demonstrating significant clinical benefit in patients with advanced melanoma compared to the gp100 peptide vaccine [70].